Diagnostics COVID-19

Quote of the Month

Karl Friston | 06/06/2020 | Quick Read

There is a pressing need for data that constrains our uncertainty about the current level of prevalent immunity. We need serological testing – not necessarily massively large-scale, but certainly sufficient to get a handle on how many people have had COVID-19 in the past few weeks. What proportion of people have had the infection and will have therefore a reduced probability of being reinfected? That’s an incredibly important unknown.

– Karl Friston, Wellcome Principal Research Fellow and Scientific Director at the Wellcome Trust Centre for Neuroimaging; Professor at the Institute of Neurology, University College London; and Honorary Consultant at the National Hospital for Neurology and Neurosurgery, London, UK

Email*

Choose a password

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the Infectious Diseases field I want to stay up to date with the Pathologist Educator field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Diagnostics COVID-19

Karl Friston

Wellcome Principal Research Fellow and Scientific Director at the Wellcome Trust

Centre for Neuroimaging; Professor at the Institute of Neurology, University College London; and Honorary Consultant at the National Hospital for Neurology and Neurosurgery, London, UK.